Objective: Matrix metalloproteinase-9 (MMP-9) is involved in the atherosclerotic process and functional polymorphisms in the MMP-9 gene affect MMP-9 expression/activity, and are associated with cardiovascular diseases. However, no study has tested the hypothesis that functional MMP-9 polymorphisms could affect MMP-9 levels in obese children. We investigated whether three MMP-9 gene polymorphisms (C-1562T (rs3918242), 90(CA) (14À24) (rs2234681) and Q279R (rs17576)), or haplotypes, affect MMP-9 levels in obese children. Methods: We studied 175 healthy control children and 127 obese children. Plasma MMP-9, tissue inhibitor of MMPs (TIMP)-1 and adiponectin concentrations were measured using enzyme-linked immunosorbent assay. Results: We found similar MMP-9 genotypes, allelic and haplotypes distributions in the two study groups (P40.05). However, we found lower plasma MMP-9 concentrations in obese subjects carrying the CC or the QQ genotypes for the C-1562T and the Q279R polymorphisms, respectively, in obese children compared with children with the other genotypes, or with non-obese children with the same genotypes (all Po0.05). Moreover, we found lower MMP-9 levels and lower MMP-9/TIMP-1 ratios (which reflect net MMP-9 activity) in obese children carrying the H2 haplotype (which combines the C, H and Q alleles for the three polymorphisms, respectively) when compared with obese children carrying the other haplotypes, or with non-obese children carrying the same haplotype (Po0.05). Conclusions: Our findings show that MMP-9 genotypes and haplotypes affect MMP-9 levels in obese children and adolescents, and suggest that genetic factors may modify relevant pathogenetic mechanisms involved in the development of cardiovascular complications associated with obesity in childhood.
Introduction
Obesity is reaching epidemic proportions worldwide, and its prevalence is increasing among children and adolescents, likely accelerating the development of cardiovascular diseases and promoting premature death in adults. 1 There is now evidence indicating that the extent of atherosclerotic lesions in children and young adults correlate positively with body mass index. 2 Therefore, the identification of key pathogenetic mechanisms and genetic markers underlying such mechanisms may help to prevent the cardiovascular complications associated with obesity. Matrix metalloproteinase-9 (MMP-9) is an endopeptidase capable of degrading components of extracellular matrix and other substrates. Altered expression and activity of MMP-9 and its major endogenous inhibitor, the tissue inhibitor of MMPs (TIMP)-1, have been implicated in atherosclerotic vascular remodeling. 3 In fact, experimental and clinical studies have clearly shown that MMP-9 is highly expressed in the atherosclerotic plaques, 4, 5 and elevated MMP-9 levels have been shown in patients with atherosclerotic diseases. 6, 7 Importantly, functional genetic polymorphisms in the MMP-9 gene modify MMP-9 levels and prognosis of patients with cardiovascular diseases. 6, 8, 9 Although MMP-9 is a major factor in cardiovascular diseases, there are few studies examining possible alterations in MMP-9 and TIMP-1 levels in obese children. [10] [11] [12] In addition, no previous study has tested the hypothesis that functional MMP-9 polymorphisms could affect MMP-9 levels in obese children and adolescents. In the present study, we aimed at investigating whether MMP-9 gene polymorphisms or haplotypes (combinations of genetic markers) affect MMP-9 levels in obese children and adolescents. We studied three functional MMP-9 polymorphisms that are known to modify MMP-9 expression or activity, 8, 13, 14 and have been associated with cardiovascular diseases: 6, 8, 9, 15, 16 the C-1562T
(rs3918242) single nucleotide polymorphism and the microsatellite (CA) 14À24 at À90 position (rs2234681), both in the promoter region of the MMP-9 gene, and the Q279R single nucleotide polymorphism (rs17576) in the exon 6. In addition, we have also assessed plasma thiobarbituric acid-reactive species (TBARS) levels (an index of oxidative stress), the homeostatic model assessment insulin resistance (HOMA IR) index and adiponectin levels in the subjects included in the present study, because we hypothesized that MMP-9 polymorphisms would not significantly affect these relevant biomarkers, although we supposed that they would affect MMP-9 levels.
Methods

Subjects
This study was approved by the Institutional Review Board at the Federal University of Juiz de Fora, Juiz de Fora, Brazil. Parents and children were informed as to nature and purpose of the study. Parents gave their written consent and children gave their verbal consent. Study populations consisted of 127 normotensive obese subjects (57 self reported as white and 70 self reported as black) recruited from the Endocrinology Ambulatory of the Adolescent and Child Institute at Juiz de Fora and from the Childhood Endocrinology Ambulatory of the IMEPEN Foundation at Juiz de Fora as outpatients. The control group consisted of 175 healthy children and adolescents (96 self reported as white and 79 self reported as black) recruited from the local community and unrelated to the obese patients.
All children underwent physical examination. Height was measured to the nearest 0.1 cm by using a wall-mounted stadiometer. Body weight was measured with a digital scale to the nearest 0.1 kg. Body mass index was calculated as the weight in kilograms divided by height in meters squared. Obesity was defined as body mass index greater than the 95th percentile, matched according to age and sex. 17 Systolic and diastolic blood pressures were measured at least three times after more than 15 min of rest, and the presence of hypertension was defined as systolic blood pressure and/or diastolic blood pressure exceeding the 95th percentile. 18 Children with hypertension were not included in this study, because hypertension may affect MMP concentrations. 19 At the time of clinical attendance, venous blood samples were collected and genomic DNA was extracted from the cellular component of 1 ml of whole blood by a salting-out method and stored at À20 1C until analyzed.
Laboratory analyses
Glucose concentrations and lipid parameters (total cholesterol, triglycerides, high-density lipoprotein cholesterol) were determined in plasma and serum, respectively, with routine enzymatic methods using commercial kits (Labtest Diagnostic SA, Lagoa Santa, Brazil). Low-density lipoprotein concentration was calculated according to the Friedewald formula. TBARS levels were determined by a fluorimetric method as previously described. 20 Enzyme immunoassays of MMP-9, TIMP-1, adiponectin and insulin Venous blood samples were collected after overnight (8-12 h) fasting, immediately centrifuged at 2000 g for 10 min at room temperature, and plasma samples were stored at À70 1C until analyzed. MMP-9, TIMP-1 and adiponectin concentrations were measured in EDTA-plasma, using commercially available enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, MN, USA) according to manufacturer's instructions. Insulin concentrations were measured in EDTA-plasma using a kit (Genese Produtos Diagnosticos, Sao Paulo, Brazil). The estimate of insulin resistance obtained by HOMA IR was calculated as previously described. 21 
DNA isolation and genotype analyses
Genotypes for the (C-1562T) polymorphism of MMP-9 were determined by PCR amplification using the primers 5 0 -GCC TGG CAC ATA GTA GGC CC-3 0 (sense) and 5 0 -CTT CCT AGC CAG CCG GCA TC-3 0 (antisense), and PCR conditions as previously described. 22, 23 The amplified products were digested with Sph I (New England Biolabs, Ipswich, MA, USA) overnight at 37 1C, producing fragments of 247 bp and 188 bp in the case of a polymorphic variant (allele T), or an undigested 435-bp fragment in the case of a wild-type allele (allele C). Fragments were separated by electrophoresis in 12% polyacrylamide gels and visualized by silver staining. To determine the genotypes for the À90(CA) [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] polymorphism, a PCR was carried out using the primers: 5 0 -GAC TTG GCA GTG GAG ACT GCG GGC A-3 0 (sense) and 5 0 -GAC CCC ACC CCT CCT TGA CAG GCA A-3 0 (antisense). The PCR conditions were performed as previously described, 22, 23 and the amplified products were separated in a 7% polyacrylamide-urea gel and visualized by silver staining. Differences in molecular weight (or number of bases), from 146 bp (CA 14 repeats) to 166 bp (CA 24 repeats), were determined by comparison with migration of a 10-bp DNA ladder (Invitrogen, Carlsbad, CA, USA) and with some samples from homozygotes that were sequenced. The alleles MMP-9 haplotypes in obese children VA Belo et al for the microsatellite À90(CA) 14-24 polymorphism were classified as 'low' (L) count when the number of CA repeats was less than 21, and as 'high' (H) when the number of CA repeats was 21 or more. 22, 23 Genotypes of Q279R (rs17576) were determined using TaqMan Allele Discrimination assay (Applied Biosystems, Foster City, CA, USA). The PCR conditions were performed according to the manufacturer's instructions.
Statistical analysis
The clinical and laboratorial characteristics of obese patients and controls were compared by unpaired t-test (normally distributed variables) or Mann-Whitney test (not normally distributed variables). The categorical variables were compared between groups by w 2 -tests. The distribution of genotypes for each polymorphism was assessed for deviation from the Hardy-Weinberg equilibrium, and differences in genotype frequency and in allele frequency between groups were assessed using w 2 -tests. A value of Po0.05 was considered statistically significant.
The Haplo.stats package (version 1.4.4; http://cran. r-project.org/web/packages/haplo.stats/index.html) was used to estimate the haplotype frequencies. The haplo.em function computes maximum likelihood estimates of haplotype probabilities using the progressive insertion algorithm. The haplo.score function was used to compute haplotype-specific score statistics to test for association. 24 Only the haplotypes with frequencies greater than 2% were taken into consideration for the haplotype-specific score analysis. The haplo.cc function was also used to calculate odds ratio and 95% confidence intervals for each haplotype. The haplotypes including genetic variants of three MMP-9 polymorphisms (C-1562T, À90(CA) 14À24 and Q279R) were: H1 (CLQ), H2 (CHQ), H3 (CHR), H4 (THR), H5 (TLR), H6 (CLR), H7 (THQ), and H8 (TLQ). Differences in haplotype frequency were further tested using a contingency table, and a value of Po0.00625 (0.05/number of haplotypes, 8; Bonferroni's correction) was considered significant to correct for the number of comparisons made.
To examine the effects of genotypes and haplotype on circulating levels of MMP-9, TIMP-1 and on MMP-9/TIMP-1 ratios, adiponectin, insulin and TBARs levels in the two study groups, we used the Kruskall-Wallis test followed by Dunn's multiple comparison test (not normally distributed variables) or analysis of variance, followed by Tukey's test (normally distributed variables). However, the H5, H6, H7 and H8 haplotypes were excluded from this analysis, because they were very rare.
Finally, to further examine the effects of MMP-9 haplotypes on MMP-9 levels, we have also performed an additional analysis. We compared MMP-9 haplotypes distributions in two groups of obese subjects: the lower quartile (LOWER-Q) group, which included subjects in the lower quartile of plasma MMP-9 distribution, and the upper quartile (UPPER-Q) group, which included subjects in the upper quartile of plasma MMP-9 distribution. We hypothesized that the haplotypes associated with lower MMP-9 levels in our initial analysis would be more commonly found in the LOWER-Q group than in the UPPER-Q group.
Results
The clinical and laboratorial characteristics of the study groups are presented in Table 1 We found no significant differences in MMP-9 concentrations and in MMP-9/TIMP-1 ratios when obese subjects were compared with controls (P40.05; Figures 1a or c) . However, obese subjects had lower plasma TIMP-1 concentrations than control subjects (Po0.05; Figure 1b ).
Supplementary Table 1 shows MMP-9 genotypes and allele frequency distributions in the two study groups. The distribution of genotypes for each polymorphism studied here showed no deviation from Hardy-Weinberg equilibrium, except for the Q279R single nucleotide polymorphism in obese patients, a finding that may be expected in cases of case-control studies. 25 No deviation from Hardy-Weinberg equilibrium was observed when considering only black or only white subjects within each study group. To examine possible effects of ethnicity on MMP-9 genotypes distribution, we carried out two different analyses. The first analysis included black and white children and adolescents, whereas the second analysis took into consideration MMP-9 haplotypes in obese children VA Belo et al only white children and adolescents, which corresponded to 48-56% of the subjects. Both analyses showed no significant differences in genotypes and alleles distributions for the three MMP-9 polymorphisms between the control group and obese group (all P40.05; Supplementary Table 1) , except for the Q279R polymorphism. The QR genotype was found with lower frequency in the obese group compared with controls (P ¼ 0.038; Supplementary Table 1) , and this finding could be due to significant deviation from Hardy-Weinberg equilibrium observed in this group. Whereas some minor differences were detected, we found no statistically significant differences in haplotype frequency distributions when the two groups of subjects were compared (Po0.05; Supplementary Table 2) . Importantly, we examined the effects of MMP-9 genotypes on plasma MMP-9 concentrations. With respect to the C-1562T polymorphism, we found that obese patients with the CC genotype had lower MMP-9 levels than control subjects with the same genotype, and lower MMP-9 levels than obese patients with the CT or TT genotypes (Figure 2a ; both Po0.05). With respect to the À90(CA) 14À24 polymorphism, we found that obese patients with the HL genotype had lower MMP-9 levels than control subjects with the same genotype (Figure 2b ; Po0.05). Finally, with respect to the Q279R polymorphism, we found that obese patients with the QQ genotype had lower MMP-9 levels than control subjects with the same genotype, and lower MMP-9 levels than obese patients with the RR genotype (Figure 2c ; both Po0.05).
In addition, we studied the effects of MMP-9 haplotypes on MMP-9 and TIMP-1 levels, and on MMP-9/TIMP-1 ratios. Although no significant differences were found in TIMP-1 levels when the different haplotype groups were compared (Figure 3b ; P40.05), we found lower MMP-9 levels and lower MMP-9/TIMP-1 ratios in obese subjects with the H2 haplotype compared with control subjects carrying the H2 haplotype, or with obese subjects with the H1, H3 or H4 haplotypes (Figures 3a and c ; all Po0.05).
Further confirming the haplotype effects on MMP-9 levels, we found that the H2 haplotype was more commonly found in obese children and adolescents with lower MMP-9 levels than in obese subjects with higher MMP-9 levels (Table 2 ;
Finally, we found that MMP-9 genotypes for the three MMP-9 polymorphisms had no effects on TIMP-1, MMP-9/ TIMP-1, adiponectin, insulin, HOMA IR index and TBARS levels (Supplementary Table 3 ; P40.05). Moreover, MMP-9 haplotypes had no effects on adiponectin, insulin and TBARS levels, and on the HOMA IR index (Supplementary Table 3 ; P40.05).
Discussion
The main novel finding reported here was that two functional MMP-9 genetic polymorphisms affect the circulating MMP-9 levels in obese children and adolescents, either when considered their single effects or when MMP-9 polymorphisms exert their combined effects within MMP-9 haplotypes. Particularly, lower MMP-9 levels were found in obese children with the CC genotype for C-1562T polymorphism, or with the QQ genotype for Q279R polymorphism, or in subjects carrying the H2 (C H Q) haplotype. Because MMP-9 levels are associated with cardiovascular diseases, 6,7 our findings suggest that obese children with these particular MMP-9 genotypes or haplotype may be at lower risk of developing cardiovascular diseases. Although increased MMP-9 levels were shown in cardiovascular diseases, [4] [5] [6] [7] we found similar MMP-9 concentrations and MMP-9/TIMP-1 in obese children compared with nonobese children. Although this finding confirms previous MMP-9 haplotypes in obese children VA Belo et al results, 12 some authors found increased circulating MMP-9
and TIMP-1 levels in obese children with coexisting hypertension. 10, 11 It is possible that hypertension may explain the discrepancies between studies, because hypertension may increase MMP-9 levels. 19 Interestingly, we found lower TIMP-1 concentrations and lower adiponectinemia in obese children compared with non-obese children, and these findings are consistent with the idea that adiponectin (an adipose-specific protein and anti-atherogenic factor) modulates TIMP-1 expression by macrophages. 26 Although several polymorphisms have been detected in the MMP-9 gene, the C-1562T polymorphism increases MMP-9 expression as a result of loss of a nuclear repressor protein binding site when the T allele is present. 8 The lower MMP-9 levels that we found in obese subjects not carrying the T allele is supported by this previous finding. Conversely, the lack of significant effects of this polymorphism in MMP-9 haplotypes in obese children VA Belo et al non-obese subjects is in line with previous findings showing that this polymorphism does not affect MMP-9 levels in healthy subjects. 22, 23 In addition, we found that absence of R allele for the Q279R polymorphism was associated with lower MMP-9 levels in obese children, and this finding agrees with previous results showing that this polymorphism affects MMP-9 activity. 14 Finally, we found no effects of the (CA) 14À24 polymorphism on MMP-9 levels, although there is evidence that this polymorphism affects MMP-9 expression. 13 Although it is clear that the adipose tissue is an active endocrine and paracrine organ that releases a large number of bioactive mediators that could modulate the expression of MMP-9 gene, 27 the present study has not been designed to define the mechanisms explaining the interactions of MMP-9 polymorphisms with childhood obesity. The analysis of haplotypes, rather than single polymorphisms, may provide improved genetic information. Here, we show for the first time that MMP-9 haplotypes may modulate the circulating MMP-9 levels in obese children and adolescents. Particularly, obese children carrying the H2 (C H Q) haplotype had lower MMP-9 levels and lower MMP-9/ TIMP-1 ratios (an index of net MMP-9 activity 28 ) than those without these genetic markers. Further supporting this finding, the comparison of extreme quartiles of MMP-9 levels confirmed that the H2 haplotype is associated with lower circulating MMP-9 levels. Interestingly, these results are in line with a previous study showing that the H2 haplotype protects against the development of hypertensive left ventricle hypertrophy. 9 Together, these findings suggest that lower MMP-9 levels associated with the H2 haplotype could be associated with protective effects against cardiovascular diseases.
In the present study, we found no association between MMP-9 genotypes or haplotypes and childhood obesity, except for the QR genotype, which was apparently more common in non-obese than in obese subjects. Although this result is not statistically significant after correction for multiple comparisons, it could be explained by HardyWeinberg deviation for this polymorphism in obese subjects, and this finding may be expected in cases of case-control studies. 25 The essentially negative results with respect to the possible association between MMP-9 polymorphisms and obesity suggest that, although MMPs have an important role in the expansion of adipose tissue mass, with intense extracellular matrix remodeling in obesity, 29 genetic markers involving MMP-9 may not be very relevant to the development of childhood obesity. We found that obese children and adolescents had higher TBARs levels (a marker of oxidative stress) when compared with non-obese controls. These results confirm that obesity is associated with increased oxidative stress and may have important implications. In fact, oxidative stress is a major MMPs activator 30 and therefore may potentiate MMPs activities in obese subjects. However, the lack of significant differences between genotype or haplotype groups, as reported here, suggest that MMP-9 polymorphisms do not interact significantly with oxidative stress to modulate MMP-9 levels in obese subjects. Although there is evidence that plasma MMP-9 levels are clearly associated with prognosis in patients with cardiovascular diseases, 6 we are not sure about the origin of circulating MMP-9. Therefore, it is not clear at this time what does it mean to have variations in MMP-9 plasma levels. Although further studies linking MMP-9 levels with relevant clinical events are necessary, an important implication of the present findings is that obese children with the CC or with the QQ genotypes for the C-1562T and the Q279R polymorphisms, respectively, or those with the H2 haplotype, may be protected against the development of cardiovascular diseases associated with obesity. These findings may suggest that MMP-9 is a relevant pharmacological target in the prevention of complications associated with obesity. It remains to be proved whether MMPs inhibitors decrease the incidence of cardiovascular events in obese subjects without these genetic markers.
In conclusion, we found evidence indicating that MMP-9 genotypes and haplotypes affect MMP-9 levels in obese children. Our findings support the notion that genetic factors may modify relevant pathogenetic mechanisms involved in the development of cardiovascular complications associated with obesity in childhood. Further studies examining the effects of MMP-9 polymorphisms on the incidence of clinical events in obese children are warranted. 's correction) . The Lower-Q group included obese subjects in the lower quartile of plasma MMP-9 distribution, whereas the Upper-Q group included obese subjects in the upper quartile of plasma MMP-9 distribution.
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